ERBB2 and gastroesophageal junction adenocarcinoma: progression after one or more prior lines of systemic therapy[20,21] Patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test, with disease progression on or after 2 or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2-targeted therapy[18]